Subclavian Introducer Set
Infusaid
FDA Clearance Information
The subclavian introducer set was cleared by the FDA via the 510(k) pathway on April 29, 1986. It is manufactured by Infusaid and classified as a Class 2 medical device.
What It Is
FDA-Cleared Indications
- Facilitation of catheter insertion into the subclavian vein for central venous access.
- Use with catheter placement procedures requiring access through the subclavian vein, according to the device labeling.
Clinical Applications
- Establishing subclavian venous access for placement of central venous catheters.
- Facilitating placement of pacemaker leads.
- Facilitating placement of defibrillator leads.
- Obtaining central venous access when a subclavian approach is selected by the treating clinician.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The available sizes, needle dimensions, dilator configuration and catheter compatibility depend on the specific set and its labeling.
- The device is intended for use by trained clinicians with sterile technique and imaging or other appropriate procedural guidance.
- Subclavian access can cause complications such as arterial puncture, bleeding, infection, pneumothorax, hemothorax, thrombosis or malposition.
- MRI safety depends on the complete system, including any catheter or implanted lead placed through the introducer; the set should not be assumed to be MRI safe without manufacturer-specific information.
- Contraindications and precautions include infection at the access site, uncontrolled bleeding risk, altered anatomy and inability to safely identify or access the subclavian vein.
Frequently Asked Questions
What are the clinical indications for the subclavian introducer set?
The device is indicated for use in procedures requiring central venous access, such as the placement of pacemaker leads and long-term central venous catheters.
What outcomes have been reported in clinical studies?
Studies report high success rates in lead placement, reduced procedure times, and fewer contrast injections with the medial approach.
What complications have been reported?
Safety data indicate a low incidence of major complications, with no significant adverse events reported in the studies reviewed.